Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.64 |
| ▸ | S1PR5 | Q9H228 | 16/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970855 | 0.90 | S1PR1 (0.65) | S1PR1S1PR5S1PR3 | |
| SCHEMBL15971001 | 0.90 | S1PR1 (0.55) | S1PR1S1PR5S1PR3 | |
| SCHEMBL15970929 | 0.83 | S1PR1 (0.62) | S1PR1S1PR5S1PR3 | |
| SCHEMBL15971181 | 0.82 | S1PR1 (0.64) | S1PR1S1PR5S1PR3 | |
| SCHEMBL15971147 | 0.82 | S1PR1 (0.64) | S1PR1S1PR5S1PR3 | |
| SCHEMBL15970975 | 0.81 | S1PR1 (0.56) | S1PR1S1PR5S1PR3 | |
| SCHEMBL15971071 | 0.78 | S1PR1 (0.59) | S1PR1S1PR5S1PR3 | |
| SCHEMBL15970788 | 0.78 | S1PR1 (0.64) | S1PR1S1PR5S1PR3 | |
| SCHEMBL4043518 | 0.78 | S1PR1 (1.00) | S1PR1S1PR5S1PR3 | |
| SCHEMBL4048911 | 0.76 | S1PR1 (0.65) | S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | claimed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | claimed |
| EP-2958913-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2015-12-30 | — | — | EP | claimed |
| WO-2014129796-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2014-08-28 | — | — | WO | claimed |
| EP-2958913-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG CHEMICAL LTD (KR) | 2018-10-03 | — | — | EP | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| EP-2958913-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014129796-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014129796-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR5 3/4885S1PR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.